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The first mechanical heart was placed by Liotta and Cooley in 1969 in a dying 
patient at the Texas Heart Institute in Houston as a 2 ½-day bridge for a transplant, 
albeit the patient died 32 hours after transplantation.1 Years later (1982) a totally 
implantable artificial heart (model Jarvik-7) was permanently implanted in a patient 
by DeVries et al at the University of Utah Medical Center in Salt Lake City, Utah, 
USA and the patient lived for 112 days.2 Subsequent attempts of implantation of 
a total artificial heart (e.g. CardioWest/SynCardia models) have limited its use as 
a bridge to transplantation, like the left- or bi-ventricular assist devices (VADs).3-7 
The SynCardia model (SynCardia Systems Inc., Tuscon, AZ) has been approved for 
compassionate use by the Food and Drug Administration (FDA) for patients with 
end-stage biventricular heart failure as a bridge to transplantation since 1985 and has 
had FDA approval since 2004.3-5 The SynCardia™ total artificial heart, weighing 180 g, 
providing a stroke volume of 70 cc, is a pneumatically driven, pulsatile system capable 
of flows of >9L/min. It is indicated for temporary use as a bridge to transplantation 
in patients with end-stage non-reversible bi-ventricular failure. Currently, the recipi-
ents of this device are hospital-bound and attached to a large pneumatic driver. The 
bridge to transplantation rate has been ~80% in >1100 implants. In 2010, the FDA 
gave conditional approval for an Investigational Device Exemption clinical study of 
the portable Freedom driver (SynCardia) (www.syncardia.com). 
Researchers and investigators are still exploring ways to develop a safe, effective 
mechanical replacement for the human heart. To date, total artificial hearts are still 
plagued with major problems, including thromboembolism, bleeding, infection and 
need for portable drivers.8-11 In contrast, ventricular assist devices (VADs)—partial arti-
ficial hearts—have had a much more successful course and are currently in widespread 
use, despite similar drawbacks and limitations (Table 1).6,7,12-14 Thoratec’s HeartMate II 
was the first continuous-flow left-VAD approved by the FDA for transplant-ineligible 
heart-failure patients (January 20, 2010) as a destination therapy. The FDA originally 
approved HeartMate II as a “bridge to transplant” in 2008; the device has been avail-
able in Europe for both indications since November 2005. Other miniaturized VADs 
approved as bridge to transplant include the HeartWare® (CE mark since 2009 and 
FDA approval since 20/11/2012), and CircuLite’s SYNERGY® Micro-pump systems 
(CE mark since 5/9/2012). 
Biventricular support can be achieved using paracorporeal biventricular assist 
devices (BiVADs), the total artificial heart (TAH), and implantable VADs.3-5,8,14,15 
However, one needs to understand the difference among these various devices. The 
total artificial heart offers biventricular “replacement”, rather than “assistance”, as the 
device is implanted orthotopically after excision and removal of the entire ventricular 
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myocardium and all four native valves.3-5,8 In contrast to pa-
tients with Bi-VADs, patients with the total artificial hearts 
have no requirements for postoperative inotropic support, 
are not afflicted by arrhythmias and have no inflow/ outflow 
cannulae-related complications. The recent development of 
a portable drive may facilitate hospital discharge. Thus, the 
total artificial heart is an effective therapeutic option for the 
treatment of patients dying of heart failure who are not suit-
able candidates for left VADs and are in need of biventricular 
support. Patients who may have a chance for recovery should 
not be considered candidates for the artificial heart. Currently, 
the main difficulty in applying this device as a destination 
therapy is its lack of portability, limited durability and ques-
tionable safety. 
Device implantation is not risk-free. Perioperative and 
postoperative bleeding, thromboembolic events and infections 
are still plaguing all devices.9,10 The continuous flow pumps, 
heralded as a major breakthrough, may increase the risk of 
gastrointestinal bleeding and have been shown to affect von 
Willebrand’s factor.11 Further limitations of the LVADs of the 
continuous flow pump type include the acute risk of right heart 
failure and the long-term morbidity of right heart dysfunc-
tion in a significant number of patients who receive LVADs. 
Thus, there has emerged a renewed interest in developing a 
continuous- (non-pulsatile) or axial-flow (which restores some 
pulsatility) biventricular support system and in the use of a 
total artificial pulsatile heart in order to address the morbidity 
associated with right heart failure.8,14,15
The growing availability and hopefully a diminishing cost13 
of mechanical circulatory support devices will allow for more 
TAbLE 1. Currently Used Ventricular Assist Devices (VADs) & Totally Implantable Artificial Heart Devices
Device (Company) Configuration/
Function
Flow Type Weight Co Use Placement/ Flow 
Direction
Longevity
Berlin Heart Excor® VAD 
(Berlin Heart)
LVAD/RVAD/
BiVAD
Pulsatile ? SV 10-60 
ml *
BTT Extracorporeal ~3y
Berlin Heart Incor® VAD 
(Berlin Heart)
LVAD Continuous 
flow
200 g →6 L/min BTT / DT Intracorporeal →6y
Jarvik 2000 (Jarvik Heart) LVAD Continuous 
flow
85 g 6 L/min BTT Intracorporeal / LV 
→ Desc or Asc Ao
→8y
HeartMate II (Thoratec) LVAD Continuous 
flow
375 g →10 L/min BTT/ DT Intracorporeal/ LVA 
→AscAo
2-8y
DuraHeart (Terumo) LVAD Continuous 
flow
540 g 2-9 L/min BTT/ DT Intracorporeal/ LVA 
→AscAo
>4y
HeartAssist 5/ **
DeBakey (MicroMed/
ReliantHeart)
LVAD Continuous 
flow
92 g →10 L/min BTT/ DT Intracorporeal/ LVA 
→AscAo
→6y
HeartWare HVAD 
(HeartWare)
LVAD Continuous
flow
160 g →10 L/min BTT/ DT Intracorporeal/ LVA 
→AscAo
→7y
Synergy (CircuLite) LVAD Continuous 
flow
< 25 g 2-4 L/min BTT/ DT Intracorporeal/ LA 
→Subclavian artery
→2y
MiFlow (WorldHeart / 
HeartWare)
LVAD Continuous 
flow
< 30 g → 6 L/min BTT/ DT Intracorporeal / 
LVA →DescAo
?
SynCardia TAH-t 
(Syncardia) ***
TAH Pulsatile 180 g > 9 L/min BTT Intracorporeal/ 
orthotopic
~4 y
Carmat (Carmat) TAH Pulsatile 900 g 3-9 L/min BTT / DT Intracorporeal / 
orthotopic
~ 5 y
AbioCor I / II ****
(AbioMed)
TAH Pulsatile 1090g (I)/ 
700g (II)
> 9 L/min BTT Intracorporeal/
orthotopic
1-2y (model 
I)/ ~5y (II)
AscAo = ascending aorta; BTT = bridge-to-transplant; CO = cardiac output; DT = destination therapy; HTx = heart transplant; LA = left atrium; 
LVA = left ventricular apex; LVAD/RVAD = left/right VAD; SV = stroke volume; TAH = total artificial heart.
* pediatric versions available, ** remote monitoring capabilities, *** an evolution of the Jarvik 7 model, renamed CardioWest and then SynCardia 
(since 2010), **** battery is charged through the skin with a special magnetic charger. Energy from the external charger reaches the internal battery 
through an energy transfer device called transcutaneous energy transmission, or TET. An implanted TET device is connected to the implanted 
battery. An external TET coil is connected to the external charger.
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widespread use than that offered by heart transplants with the 
limited supply of donor hearts and will allow for the imple-
mentation of clinical trials and technology improvements at a 
scale that cannot be attained by heart transplantation. Thus, 
we may see a proliferation of complex, more miniaturized 
implantable devices and more durable and sustainable with 
each generation.
However, despite advances in device technology, the dream 
will remain alive for a totally implantable, self-contained 
and energy-sufficient device, which currently still remains a 
major challenge. Recently (December 18, 2013), a glimpse of 
real hope was offered by French Dr Alain Carpentier whose 
team implanted a new fully implantable artificial heart manu-
factured by Carmat, in a 75-year old patient at the Georges 
Pompidou European Hospital in Paris (http://www.carmatsa.
com/). The device comprises two chambers, each divided by 
a membrane that holds hydraulic fluid on one side (http://
en.wikipedia.org/wiki/Artificial_heart). A motorized pump 
moves hydraulic fluid in and out of the chambers, and that fluid 
causes the membrane to move; blood flows through the other 
side of each membrane. The blood-facing side of the mem-
brane is made of tissue obtained from bovine pericardium, to 
make the device more biocompatible. The Carmat device also 
uses valves made from bovine heart tissue and has sensors to 
detect increased pressure within the device. That information 
is sent to an internal control system that can adjust the flow 
rate in response to increased demand, such as when a patient 
is exercising. This distinguishes it from previous designs that 
maintain a constant flow rate. The device weighs 900 grams; 
it requires the patient to carry around an additional Li-Ion 
battery. The device will be used as destination therapy; its pro-
jected lifetime is estimated around 5 years (230 million beats). 
C o N C L U s I o N
A fully implantable autonomous artificial heart without 
any external components remains a major challenge. Apart 
from other major technical demands, it is dependent on the 
capacity of the implanted battery, which should be charged 
transcutaneously.16,17 However, this technology is still in the 
beginning; MIT scientists have founded a company, WiTricity 
(Watertown, MA), which has partnered with Thoratec Corp. 
(Pleasanton, CA) to develop a fully implanted left-VAD (www.
mddionline.com/article/wireless-power-medical-devices). 
For now, the availability of the Freedom® portable driver that 
powers the SynCardia temporary Total Artificial Heart will 
allow stable patients to live life at home, while smaller devices 
are going to be available (e.g. the 50cc version in addition to 
the 70cc SynCardia temporary Total Artificial Heart) to fit 
women and younger and smaller stature patients. Finally, the 
first-in-man implantation of Carmat’s bioprosthetic artificial 
heart is most encouraging (http://www.carmatsa.com/). 
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